Vimarsana
Biggest News Aggregation in the World

Page 48 - Confidence Interval News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Confidence Interval. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Confidence Interval Today - Breaking & Trending Today

Meningococcal NmCV-5 Vaccine is effective in 2-to-29-year-olds in Mali and Gambia - Vimarsana News

Meningococcal NmCV-5 Vaccine is effective in 2-to-29-year-olds in Mali and Gambia

Bookmark 1. In this randomized controlled trial, the NmCV-5 vaccine elicited an immune response that was noninferior to the MenACWY-D vaccine in two-to-29-year-olds in Mali and Gambia. 2. The NmCV-5 vaccine had a similar incidence of adverse events as compared to the MenACWY-D vaccine. Evidence Rating Level: 1 (Excellent) Study Rundown: The highest incidence of

Supervised hospital walking program reduces the need for nursing care - Vimarsana News

Supervised hospital walking program reduces the need for nursing care

1. A supervised walking program was associated with reduced discharge rates to skilled-nursing facilities (SNF) from a Veterans Affairs (VA) hospital. 2. The supervised walking program did not result in a reduced length of hospital stay or a lower number of inpatient falls. Evidence Rating Level: 1 (Excellent) Study Rundown: Inactivity during hospitalization has been

The 2 Minute Medicine Podcast Episode 18 | 2 Minute Medicine - Vimarsana News

The 2 Minute Medicine Podcast Episode 18 | 2 Minute Medicine

Welcome to the 2 Minute Medicine Podcast, summarizing the latest medical studies, curated and written by practicing physicians. On this podcast, twice a month, we cover the latest in healthcare news and research evidence. Our episode is live! Episode Description We begin this episode by discussing our article of the week from the New England

Meningococcal NmCV-5 Vaccine is effective in 2-to-29-year-olds in Mali and Gambia - Vimarsana News

Meningococcal NmCV-5 Vaccine is effective in 2-to-29-year-olds in Mali and Gambia

1. In this randomized controlled trial, the NmCV-5 vaccine elicited an immune response that was noninferior to the MenACWY-D vaccine in two-to-29-year-olds in Mali and Gambia. 2. The NmCV-5 vaccine had a similar incidence of adverse events as compared to the MenACWY-D vaccine. Evidence Rating Level: 1 (Excellent) Study Rundown: The highest incidence of meningitis

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura cTTP - Vimarsana News

Pivotal Phase 3 Data Presented at ISTH 2023 Congress Spotlight TAK755 Prophylaxis for Patients with Congenital Thrombotic Thrombocytopenic Purpura cTTP

Takeda TSE 4502NYSETAK today presented favorable interim results from a global pivotal Phase 3 randomized controlled openlabel crossover trial evaluating the safety and efficacy of TAK755 recombinant ADAMTS13 replacement therapy for the prophylactic treatment of congenital thrombotic thrombocytopenic purpura cTTP and pharmacokinetics PK characteristics of TAK755 as well as longterm data on TAK755 prophylaxis from a Phase 3b continuation study.